Triple-negative breast cancer (TNBC), i.e., those not expressing ER, PR, or HER2, represent ~ 10–20% of all cases, have poorer prognosis than HER2+ or hormone receptor-positive tumors, and are generally characterized by an aggressive clinical course [2]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.